ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Should autologous HSCT be a first-line option in highly active MS? Commentary.

Anna Karin HedströmPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.